• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Canada approves Tandem Diabetes Caree’s advanced hybrid closed-loop insulin pump

November 23, 2020 By Chris Newmarker

Tandem Diabetes CareTandem Diabetes Care (NSDQ:TNDM) announced today that Health Canada has approved its t:slim X2 insulin pump with Control-IQ technology.

The news comes nearly a year after the U.S. launch of the t:slim X2 with Control-IQ. All in-warranty t:slim X2 pump users in Canada will be able to add Control-IQ technology to their existing pump via a remote software update — starting in March 2021, and new t:slim X2 insulin pumps with Control-IQ tech will start shipping in Canada in Q1 2021.

The Control-IQ technology — which integrates with Dexcom G6 continuous glucose monitoring — requires no fingersticks for calibration or diabetes treatment decisions. The Control-IQ tech uses CGM readings to predict glucose values 30 minutes ahead and can increase, decrease, or stop basal insulin delivery to help keep glucose in-range (3.9-10 mmol/L). The technology can automatically correct boluses, and there are optional sleep and exercise settings.

“The t:slim X2 insulin pump with Control-IQ technology is the most advanced automated insulin dosing system available in the world and is a testament to our commitment to improving the lives of people with diabetes,” Tandem CEO John Sheridan said in a news release. “We are thrilled to be able to bring the benefits of this advanced hybrid closed-loop system to the Canadian diabetes community.”

Filed Under: Diabetes, Featured Tagged With: Health Canada, insulin, Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS